AI-generated analysis. Always verify with the original filing.
ProMIS Neurosciences Inc. reported financial results for the year ended December 31, 2025, with a net loss of $39.7 million, cash of $6.1 million, R&D expenses of $33.4 million, and G&A expenses of $6.8 million. The company completed enrollment of 144 patients in the PRECISE-AD Phase 1b trial for PMN310 and closed a $75.5 million private placement in February 2026, providing cash runway through 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 25, 2026 104 Cover P
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $39.70 | |
| Research and Development Expenses | $33.40 | |
| General and Administrative Expenses | $6.80 |